Please click here to skip to the HCM 101 satellite program for APPs

General Sessions: McCormick Place, South Building, Room 406a

Please note: Busing begins at at 6:30. Coffee and a continental breakfast will be available in satellite rooms.

7:00 am - 7:45 am

Satellite A: BraveHeart Bio
Satellite B: Bristol Myers Squibb

Room 405a
Room 405b

8:00 am - 9:30 am

Session 1 - The Latest in HCM Therapy

1. Apply current evidence and guideline-based strategies to select first-line and individualized therapies for patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
2. Evaluate current and emerging evidence for cardiac myosin inhibitors in special HCM populations, including pediatric patients and individuals with non-obstructive HCM.
3.  Describe the therapeutic pipeline for HCM, including next-generation cardiac myosin inhibitors, sarcomere modulators, and novel metabolic or disease-modifying approaches such as SGLT-based therapies.

Room 406a

8:35 am - 8:50 am

Update on Therapies for Non-Obstructive HCM

Steve Ommen, Mayo Clinic

8:50 am - 9:05 am

What's Coming

Sara Saberi, University of Michigan

9:05 am - 9:30 am

Making Choices: How to Treat Symptomatic Obstructive HCM (panel discussion)

Eric Smith, University of Michigan; Matt Martinez, Mayo Clinic; Michele Michels, Erasmus University; Daniel Swistel, NYU Langone

9:45 am  - 10:45 am

Session 2 - Oral Abstracts

Room 406a

10:45 am - 11:15 am

The Eugene Braunwald, MD, Lecture

Scott Solomon, Professor of Medicine, The Edward D. Frohich Distinguished Chair at Harvard University / Brigham and Women's Hospital

11:15 am - 12:45 pm

LUNCH. A box lunch will be provided to attendees prior to the start of the Satellite Sessions

406b

11:45 am - 12:45 pm

Satellite C: Pfizer
Satellite D: Cytokinetcs

405a
405b

1:00 pm -2:15 pm

Session 3 - Cool New Gadgets and Interventions

1. Compare implantable cardioverter-defibrillator options for primary and secondary prevention of sudden death in patients with HCM and identify patient factors that guide device selection.
2. Evaluate contemporary strategies for atrial fibrillation ablation, including timing, repeat procedures, energy source selection, and when to stop pursuing ablation.
3. Describe emerging catheter-based and surgical approaches to septal reduction therapy.

406a

1:00 pm - 1:15 pm

ICDs: When to Choose EV-ICD vs. sICD vs. TV-ICD

Sunny Kapur, Harvard University / Brigham and Women's Hospital

1:15 pm - 1:30 pm

AF Ablation: When, How Many, What Energy, When to Call it Quits

Bradley Knight, Northwestern Memorial Hospital

1:30 pm - 1:45 pm

New Approaches to Catheter-Based SRT

Jaffar Khan, National Institutes of Health

1:45 pm - 2:00 pm

New Approaches to Surgical Myectomy

Nick Smedira, Cleveland Clinic

2:00 pm - 2:15 pm

Panel Discussion

All Session 3 presenters and moderators

2:15 pm - 3:15 pm

Session 4 - Late Breaking Oral Abstracts

406a

3:30 pm - 4:45 pm

Session 5 - Living Well with HCMS, Now and Into the Future

1. Explain how genetic information can improve understanding, risk assessment, and prevention strategies in hypertrophic cardiomyopathy.
   Describe emerging approaches to defining and characterizing hypertrophy, including distinctions between sarcomeric HCM and other contributors to increased wall thickness.
2. Evaluate the impact of obesity, cardiometabolic stress, and exercise on HCM outcomes and patient-centered disease management.

406a

3:30 pm - 3:45 pm

How Can Genetic Information Help us Understand and Prevent Disease?

Adam Helms, University of Michgan

3:45 pm - 4:00 pm

Redefining HCM: New Approaches to Characterizing Hypertrophy

Charlotte Manisty, University College London

4:00 pm - 4:15 pm

Beyond the Sarcomere: The Impact of Obesity and Cardiometabolic Stress

John Ostrominsky, Harvard University/ Brigham and Women's Hospital

4:15 pm - 4:30 pm

Exercise in HCM

Ben Levine, Texas Health Resources / UT Southwestern Medical Center 

4:30 pm - 4:45 pm

Panel Discussion

All Session 5 speakers and moderators

5:00 pm - 6:15 pm

SPECIAL SATELLITE EVENT:
HCM 101 - How to Create an HCM Care Team

1. Describe the pathophysiology and clinical presentation of obstructive HCM, including the mechanisms of left ventricular outflow tract obstruction and common symptoms that prompt evaluation.
2. Identify key diagnostic strategies for obstructive HCM, including the role of history, physical examination, and echocardiography with provocative maneuvers.
3. Apply practical strategies for implementing and managing a cardiac myosin inhibitor clinic, including patient selection, medication initiation and monitoring, echocardiographic follow-up, safety considerations, documentation workflows, and patient education.

405a

5:00 pm - 5:25 pm

Introduction to oHCM

Alex de Feria, Penn Medicine, University of Pennsylvania

5:25 pm - 6:15 pm

Setting up a CMI Clinic: Tips and Tricks (Panel Discussion)

Amy Marzolf, NP, Penn Medicine, University of Pennsylvania; Rachel Lavelle, PharmD, University of Chicago Medicine; Andrew Willeford, PharmD,  UC San Diego Health; Matt Prizand, NP, Brigham and Women's Hospital; Fiona Halloran, PA-C, Children's Hospital of Philadelphia